{
  "name" : "dacemirror.sci-hub.se_journal-article_feb9942e7c7dcd8781bc8a53d58c5e16_ke2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Mitigation of Amyloidosis with Nanomaterials",
    "authors" : [ "Pu Chun Ke", "Emily H. Pilkington", "Yunxiang Sun", "Ibrahim Javed", "Aleksandr Kakinen", "Guotao Peng", "Feng Ding", "Thomas P. Davis" ],
    "emails" : [ "pu-chun.ke@monash.edu;", "thomas.p.davis@monash.edu" ],
    "sections" : [ {
      "heading" : null,
      "text" : "RESEARCH NEWS\n1901690 (1 of 7) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de"
    }, {
      "heading" : "Mitigation of Amyloidosis with Nanomaterials",
      "text" : ""
    }, {
      "heading" : "Pu Chun Ke,* Emily H. Pilkington, Yunxiang Sun, Ibrahim Javed, Aleksandr Kakinen,",
      "text" : ""
    }, {
      "heading" : "Guotao Peng, Feng Ding, and Thomas P. Davis*",
      "text" : "Prof. P. C. Ke, E. H. Pilkington, I. Javed, Dr. A. Kakinen, Prof. T. P. Davis ARC Center of Excellence in Convergent Bio-Nano Science and Technology Monash Institute of Pharmaceutical Sciences Monash University 381 Royal Parade, Parkville, VIC 3052, Australia E-mail: pu-chun.ke@monash.edu; thomas.p.davis@monash.edu Prof. Y. Sun, Prof. F. Ding Department of Physics and Astronomy Clemson University Clemson, SC 29634, USA\nDOI: 10.1002/adma.201901690\nAmyloid fibrils were considered a major culprit for cell degeneration till the 1990s.[5] Recent studies, however, have implicated the oligomers as the most toxic species. This toxicity is believed to arise from the interactions of the oligomers with cell membranes, proteins, chaperones, organelles, biometals, and small ligands to induce membrane damage, endoplasmic reticulum stress, and reactive oxygen species (ROS)[6] (Figure 1). The ambiguity surrounding the exact cause of oligomer toxicity originates from the transient and heterogeneous nature of the aggregation species, compounded by the coexistence of primary and sec-\nondary nucleation,[7] the kinetics of fibrillar association, dissociation, and fragmentation, and the polymorphism of amyloid fibrils, driven by thermodynamic transitions. It has now been verified that the crystalline form, rather than the fibrils, is the most stable state of amyloid proteins.[8]\nHere, we outline the biophysical foundation of amyloid aggregation, and summarize current mitigation strategies involving nanomaterial and multifunctional nanomaterial composite inhibitors in silico, in vitro, and in vivo. We note the occasional divergence between protein aggregation and toxicity, and discuss the implications of the protein “corona”[9] enriched on amyloid fibrils in a biological milieu. This presentation highlights the structural and physicochemical attributes of nanomaterials and multifunctional nanocomposites for targeting amyloidosis."
    }, {
      "heading" : "1.1. In Silico Mitigation of Amyloidosis with Nanomaterials",
      "text" : "Understanding the aggregation pathways and uncovering the structures and dynamics of oligomeric intermediates are crucial for the design of antiamyloid strategies. The heterogeneous and\nAmyloidosis is a biophysical phenomenon of protein aggregation with biological and pathogenic implications. Among the various strategies developed to date, nanomaterials and multifunctional nanocomposites possessing certain structural and physicochemical traits are promising candidates for mitigating amyloidosis in vitro and in vivo. The mechanisms underpinning protein aggregation and toxicity are introduced, and opportunities in materials science to drive this interdisciplinary field forward are highlighted. Advancement of this emerging frontier hinges on exploitation of protein self-assembly and interactions of amyloid proteins with nanoparticles, intracellular and extracellular proteins, chaperones, membranes, organelles, and biometals."
    }, {
      "heading" : "Biomedical Applications",
      "text" : ""
    }, {
      "heading" : "1. Introduction",
      "text" : "Human amyloids are proteinaceous substances whose crossbeta structure was first resolved in 1968 by X-ray diffraction.[1] It is now understood that virtually all proteins possess the capacity of forming amyloid fibrils under natural or artificial conditions.[2] Depending on their biological roles, amyloid proteins can be classified as pathogenic, such as amyloid beta (Aβ), alpha synuclein (αS), and human islet amyloid polypeptide (IAPP), associated with Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D), respectively, or functional, such as curli and FapC, the major constituents of bacterial amyloids.[3]\nRegardless of their origin and sequence, amyloids are stiff nanostructures held together by hydrogen bonds between unfolded peptides/proteins, assembled from in- or out-ofregister β sheets through hydrophobic interactions, and further strengthened by stacking of aromatic moieties along the fibrillar backbone. Amyloid proteins fibrillate through the three kinetic phases of nucleation, elongation, and saturation in primary nucleation, generating oligomers, protofibrils, and amyloid fibrils en route with a metal-loading capacity.[4]\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201901690.\nProf. Y. Sun Department of Physics Ningbo University Ningbo 315211, China Dr. G. Peng Institute of Environmental Medicine Karolinska Institutet Stockholm SE-17177, Sweden Prof. T. P. Davis Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane, Qld 4072, Australia\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (2 of 7)\nmetastable nature of the aggregation intermediates presents tremendous challenges to experimental characterizations of these species. Using atomistic discrete molecular dynamics simulations (a rapid and predictive molecular dynamics algorithm) with model peptides, including the amyloidogenic fragments of IAPP, Aβ, and αS,[10a–c] we obtained an aggregation free energy landscape as a function of the aggregation size and fraction of β-sheet content, where the peptides first assembled into low β-sheet oligomers followed by conformational transitions to β-sheet rich oligomers and by elongation to cross-β fibrils (Figure 2A). Among β-sheet rich oligomers, β-barrels have been found as common intermediates of different amyloidogenic peptides.[10c] With well-defined 3D structures, β-barrel intermediates have been postulated as the candidates of cytotoxic oligomers that cause membrane leakage by forming “amyloid pores.”[10c,d]\nTo eliminate toxic β-sheet rich oligomers, an amyloidmitigating strategy should effectively increase their free energy levels in the aggregation landscape. This can be achieved by stabilizing the less toxic species, including the monomers, low β-sheet oligomers, or fibrils (Figure 2A). For example, OH-terminated polyamidoamine dendrimers encapsulated the amyloidogenic core of IAPP inside the hydrophobic micellar interior, stabilizing IAPP as monomers and hindering their further oligomerization and fibrillization (Figure 2B).[10e] This predicted inhibition was validated by toxicity assays employing both pancreatic beta cell lines and mouse islets. An alternative\nstrategy is to stabilize low β-sheet content oligomers. Graphene oxide and graphene quantum dots (GQDs) have been shown to bind IAPP species strongly via hydrophobic interactions, aromatic stacking, hydrogen bonding, and salt-bridging.[10f,g] Bound low β-sheet oligomers were stabilized in this nontoxic form as hydrogen bonding between nanosheet hydroxyls and peptide backbones hindered the formation of interpeptide hydrogen bonds, thus truncating further β-sheet development. (Figure 2B). Accelerating fibrillization by reducing the aggregation energy barrier presents an additional strategy to reduce the lifetime and population of oligomers, thus mitigating their associated toxicity (Figure 2B). For example, gold nanoparticles coated with β-lactoglobulin amyloid fragments (bLg-AuNPs) were demonstrated by computer docking to seed the aggregation of IAPP.[10h] Star polymers possessing rigid arms and a rodlike morphology served as a template for IAPP binding and conversion into extended β-sheets, which accelerated IAPP aggregation by a reduced aggregation barrier.[10h] Overall, reducing the population of toxic β-sheet rich oligomers, rather than inhibition of peptide/protein aggregation, appears more essential for amyloidosis mitigation."
    }, {
      "heading" : "1.2. In Vitro Mitigation of Amyloidosis with Nanomaterials",
      "text" : "Phenolic and synthetic small molecules[11a,b] have shown potency in inhibiting amyloid aggregation, resulting from their\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (3 of 7)\npropensity to complex with amyloid proteins or intercalate into the amyloidogenic regions of aggregating species. Flavonoids such as resveratrol, curcumin, and epigallocatechin gallate allow scavenging of radicals associated with lipid peroxidation of cell membranes. In this context, flavonoids disrupt amyloid aggregation while protecting surrounding tissue against ROS generated through amyloidosis. The molecular promiscuity and low solubility of polyphenols, however, limit their application in vivo.\nThe roles of physiological metals on cell metabolism and degeneration have long been known in biology. Amyloid motifs such as cysteine can host heavy metal ions through coordination, an effect which has been exploited beyond the scope of amyloidosis to wastewater purification and iron fortification.[12a,b] Recent studies have also shown that amyloids can act as pseudo-enzymes via sequestration of metal ions,[13] potentially altering materials that interface with the amyloid surface. Since metal and metal oxide nanoparticles can readily release metal ions, while Fe3+, Cu2+, and Zn2+, for example, are known to impact amyloidosis in vivo, there is a large potential for exploiting metal nanoparticles to combat amyloidosis and amyloid diseases.\nCeria nanocrystals, ZnO nanoparticles, carbon nanotubes, graphene oxide, GQDs, as well as transition-metal dichalcogenide nanosheets (TMDs, such as tungsten disulphide WS2 and molybdenum disulphide MoS2) can sequester toxic amyloid species, while their surface functionalization can enhance\nantiamyloid targeting and delivery.[14a–g] Interfacing fluorescently tagged resveratrol with graphene oxide, for example, created a new probe for AD screening.[15] Gold nanoparticles appear to be excellent antiamyloid agents and can act as fibrillization probes through binding with amyloid cysteines.[16] Gladytz et al. proposed that the amyloid aggregation of IAPP and prion protein SUP35 hinged on a balance between peptide– nanoparticle and peptide–peptide interactions,[17] a statement supported by our observations with iron oxide and silver nanoparticles coated with citrate and polyethylene glycol (PEG).[18]\nAs cationic nanomaterials and multifunctional nanocomposites are prone to protein fouling and membrane damage,[19] anionic or neutrally charged materials may prove superior candidates against amyloidosis. Accordingly, OH-terminated polyamidoamine dendrimer prevented IAPP aggregation and toxicity in MIN6 pancreatic beta cells and mouse islets.[10e] In addition, reversible addition–fragmentation chain-transfer synthesis of hyperbranched PEG polymers incorporating a dopamine moiety inhibited αS aggregation.[20]\nIt is noted that amyloid aggregation inhibition may not always prevent cell degeneration, as toxic oligomeric species may be eliminated through accelerated aggregation. For example, poly (2-hydroxyl ethyl acrylate) star polymers accelerated IAPP fibrillization through formation of polymer-IAPP complexes, thereby reducing IAPP-elicited cytotoxicity in pancreatic beta cells and islets (Figures 2 and 3).[10i] Similarly, trodusquemine enhanced the aggregation but reduced the toxicity of Aβ42 in a C. elegans\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (4 of 7)\nmodel[21] (Figure 3). These examples mirror the natural fibrillization of Pmel17 in melanocytes, which produces melanin via rapid aggregation to avoid toxicity.[22]\nThe capacity of amyloid species to form a “protein corona” in biological media has been recently established. IAPP amyloid fibrils exposed to cell culture media acquired overnight coronae of linear proteins and multidomain proteins of structural plasticity.[9] Multiple proteins identified in the amyloid-protein corona correlated with amyloid-associated proteins extracted from cerebral plaques, with those enriched corresponding to metabolic and biological pathways such as apoptosis and blood clotting. To attain successful translation of antiamyloid agents from in vitro to in vivo, the behaviour of amyloid in complex biological environments must be elucidated."
    }, {
      "heading" : "1.3. In Vivo Mitigation of Amyloidosis with Nanomaterials",
      "text" : "In vivo strategies against amyloidosis have been mostly explored with mouse models, via three approaches: 1) using transgenic (tg) mice which overexpress human amyloid\nproteins, 2) eliciting the disease symptoms by directly injecting amyloid proteins into the targeted tissues of wild-type (WT) animals, and 3) extracting the affected organs from tg animals and treating them with nanomaterials and multifunctional nanocomposites, ex vivo. Additionally to behavioral defects and amyloid plaque deposits in the tissues, neurotransmitters such as tyrosine hydroxylase for PD, acetylcholine esterase, serum glutamate, and GABA (γ-amino butyric acid) for AD, and insulin levels for T2D were monitored as the disease indicators.[24a,b]\nTo combat AD and PD in vivo, nanoparticles and nanocomposites should be capable of translocation across the blood–brain barrier (BBB) and targeting amyloid deposits in the brain. Upon administration to tg2576 mice via the carotid artery, iron nanoparticles complexed with antibody IgG4.1 translocated cross the BBB and accumulated inside the Aβ plaques in cerebral adventitia of meningeal tissues, as well as cerebrovascular cortical arteries/arterioles.[24b] However, antibodies achieved little success against amyloidosis in human preclinical studies, due to nonspecific immune reactions and meningoencephalitis.[25]\nAlternatively, peptides TGNYKALHPHNG (TGN) and QSHYRHISPAQV (QSH), screened via mirror image phage\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (5 of 7)\ndisplay to target the BBB and Aβ fibrils, were conjugated on PEGylated-polylactic acid nanoparticles (50 nm) and injected intravenously into adult nude mice pretreated with cerebroventricular injection of Aβ. Upon reaching the hippocampus, the nanoparticles showed high binding affinity for Aβ lesions. KLVFF, a 5-residue sequence from Aβ42, targeted Aβ plaques in APPswe/PS1dE9 transgenic mice (Figure 3).[23b] The peptide was conjugated to chitosan nanoparticles (30 nm) via a PEG cross-linker, and a Beclin-1 protein was additionally attached to induce autophagy. This unique approach selectively captured Aβ in vivo via hydrogen bonding between nanoparticlebound KVLFF and the KVLFF segment of the Aβ fibrils. The particle-Aβ aggregates were then endocytosed to intracellular lysosomes for degradation, consequently clearing ≈59% and 32% of insoluble and soluble Aβ in vivo and restoring memory deficits in tg mice. Similarly, tethering whole Aβ40 on the surfaces of Gd or Fe nanocrystals resulted in accumulation of the nanocrystals in the Aβ plaques of tg mice and aided in micromagnetic resonance imaging of the plaques.[26] However, the BBB permeability of these metal nanocrystals was limited, and codelivery with mannitol was suggested to temporarily open the BBB. This strategy may be employed for in vivo targeting of IAPP and αS deposits in pancreatic and cerebral tissues.\nBiomimetic nanodiscs (33 nm), constructed from apolipoprotein E3 (ApoE3) and high-density lipoproteins, transcytosed across the BBB via ApoE3 specific receptors upon intravenous administration into Aβ-treated WT mice—avoiding accumulation of a protein “corona” within the plasma and cerebrospinal fluid—and targeted Aβ monomers/oligomers, promoting astrocyte- and microglial-based Aβ clearance.[27] Bare GQDs crossed the BBB via endocytosis by brain microvascular endothelial cells and subsequently cleaved off αS fibrils, inducing their clearance from αS-treated WT mice and restoring memory.[24a]\nTo target IAPP fibrillization, β-sheet rich bLg amyloid fragments were supported on multiwalled carbon nanotubes that subsequently sequestered the toxic IAPP species preinjected into zebrafish (Danio rerio) embryos,[28] forming a bLg-IAPP double protein coronae via hydrogen bonding and hydrophobic interaction. GQDs and chiral silica nanoribbons were also demonstrated as effective against IAPP amyloidosis in zebrafish larvae (Figure 3).[10g,29] Specifically, GQDs bound IAPP through electrostatic and hydrogen bonding, driving the peptide fibrillization off-pathway to eliminate toxic intermediates in vivo.[10g] Right-handed silica nanoribbons acted as nucleation sites for IAPP to fibrillate perpendicularly to the ribbon axis, thereby eliminating IAPP toxicity in the larvae.[29a] Zebrafish models allowed real-time imaging of amyloidosis and associated behavioral pathologies in vivo with nanoliter sample volumes, and are especially suitable for high-throughput screening of nanoparticle and nanocomposite inhibitors."
    }, {
      "heading" : "2. Summary and Outlook",
      "text" : "As drug-delivery systems, nanoparticles hold the promise to improve the therapy of central nervous system diseases such as brain tumor, Alzheimer's disease, and stroke.[30] Regardless of their chemical composition, structure, size, and morphology, nanoparticles can perturb the structures of amyloid proteins\nthrough nonspecific interactions. On the other hand, due to the transient and heterogeneous nature of oligomers, their concept, structure, and toxicity profiles are not well defined and, consequently, not well understood.[10b,31a–c] The average molecular weight of the oligomers of Aβ, for example, can vary from tens to hundreds of kDa, depending on how the molecular weight is estimated and how the peptides are incubated or chemically modified. In the light of these complexities, it is therefore essential to evaluate not only in vitro but also in vivo performances of nanomaterials and multifunctional nanocomposites as amyloidosis inhibitors.\nGenerally, amphiphilic nanoparticles entail dipolar and hydrophobic interactions with amyloid proteins, while hydrogen bonding and pi-stacking between the nanoparticles and amyloid proteins can outcompete and disrupt protein aggregation from eliciting toxicity. These intended interactions, however, are subjected to interference and screening by the abundant molecular species in vivo. This aspect, together with the translocation efficacy across the BBB, remains one of the biggest challenges for the field of amyloidosis mitigation to deliver its promise at future clinical trials.\nGiven the fact that amyloid protein fibrils and protofibrils are predominantly left-handed, chirality is a parameter to be exploited for the design of nanoparticle inhibitors.[29a–c] In vivo delivery or sequestration of biometals against amyloidosis is a new arena pertinent to chemical and materials sciences and engineering as well as medicine, and the strategy of coloading a metal-ion chelator and an amyloidosis inhibitor for their controlled release has been recently demonstrated.[32] For in vivo studies, the expanding list of animal models, from mice to C. elegans and to zebrafish embryos and larvae, offers flexibility for testing a slew of nanomaterials and nanocomposites against amyloid diseases.\nMachine learning is a relatively new concept in the field of amyloidosis, whose goals are to guide the design and screening of nanoparticle inhibitors against the benchmarks of protein aggregation, toxicity inhibition, protein corona avoidance, as well as efficacies of BBB translocation and amyloidosis targeting. However, the lack of a large body of reliable benchmark data in the field of amyloidosis hinders the immediate application of machine learning.\nIn addition to phenotype interference, exposure to amyloid proteins may induce changes in neuronal/pancreatic beta cells and tissues from genetic to proteinic levels, and such effects may be mitigated by nanoparticle inhibitors. More efforts may focus on the improvement of test approaches, such as real-time quantitative polymerase chain reaction, tandem mass spectroscopy (MS/MS) and emerging omics-based technologies, as well as the connection between phenotype endpoints and changes of gene or protein expression, which will serve to identify new biomarkers for AD and PD-like symptoms and foster a complete understanding of the regulation mechanisms of amyloidosis by nanomaterials and multifunctional nanocomposites."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported by ARC Project No. CE140100036 (T.P.D.), NSFCAREERCBET-1553945 (F.D.), NIH MIRAR35GM119691 (F.D.),\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (6 of 7)\nand AFTAM Research Collaboration Award (T.P.D. and P.C.K.). Pilkington acknowledges the support of an Australian Government RTP scholarship."
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Keywords",
      "text" : "amyloidosis, nanocomposites, nanomaterials, oligomers\nReceived: March 18, 2019 Revised: April 15, 2019\nPublished online:\n[1] E. D. Eanes, G. G. Glenner, J. Histochem. Cytochem. 1968, 16, 673. [2] T. P. J. Knowles, M. Vendruscolo, C. M. Dobson, Nat. Rev. Mol. Cell\nBiol. 2014, 15, 384. [3] R. P. Friedland, M. R. Chapman, PLoS Pathog. 2017, 13, e1006654. [4] K. J. Barnham, A. I. Bush, Chem. Soc. Rev. 2014, 43, 6727. [5] J. Hardy, D. J. Selkoe, Science 2002, 297, 353. [6] P. C. Ke, M.-A. Sani, F. Ding, A. Kakinen, I. Javed, F. Separovic,\nT. P. Davis, R. Mezzenga, Chem. Soc. Rev. 2017, 46, 6492. [7] S. I. A. Cohen, S. Linse, L. M. Luheshi, E. Hellstrand, D. A. White,\nL. Rajah, D. E. Otzen, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, Proc. Natl. Acad. Sci. USA 2013, 110, 9758. [8] J. Adamcik, R. Mezzenga, Angew. Chem., Int. Ed. 2018, 57, 8370. [9] E. H. Pilkington, O. J. R. Gustafsson, Y. Xing, J. Hernandez-Fernaud,\nC. Zampronio, A. Käkinen, A. Faridi, F. Ding, P. Wilson, P. C. Ke, T. P. Davis, ACS Nano 2018, 12, 6066. [10] a) Y. Sun, B. Wang, X. Ge, F. Ding, Phys. Chem. Chem. Phys. 2017, 19, 28414; b) Y. Sun, A. Kakinen, E. H. Pilkington, Y. Xing, C. Zhang, T. P. Davis, P. C. Ke, F. Ding, Biochim. Biophys. Acta, Mol. Basis Dis. 2019, 1865, 434; c) Y. Sun, X. Ge, Y. Xing, B. Wang, F. Ding, Sci. Rep. 2018, 8, 10353; d) S. A. Sievers, J. Karanicolas, H. W. Chang, A. Zhao, L. Jiang, O. Zirafi, J. T. Stevens, J. Munch, D. Baker, D. Eisenberg, Nature 2011, 475, 96; e) E. N. Gurzov, B. Wang, E. H. Pilkington, P. Chen, A. Kakinen, W. J. Stanley, S. A. Litwak, T. P. Davis, F. Ding, P. C. Ke, Small 2016, 12, 1615; f) M. Li, X. Yang, J. Ren, K. Qu, X. Qu, Adv. Mater. 2012, 24, 1722; g) M. Wang, Y. Sun, X. Cao, G. Peng, I. Javed, A. Kakinen, T. P. Davis, S. Lin, J. Liu, F. Ding, P. C. Ke, Nanoscale 2018, 10, 19995; h) I. Javed, Y. Sun, J. Adamcik, B. Wang, A. Kakinen, E. H. Pilkington, F. Ding, R. Mezzenga, T. P. Davis, P. C. Ke, Biomacromolecules 2017, 18, 4316; i) E. H. Pilkington, M. Lai, X. Ge, W. J. Stanley, B. Wang, M. Wang, A. Käkinen, M.-A. Sani, M. R. Whittaker, E. N. Gurzov, F. Ding, J. F. Quinn, T. P. Davis, P. C. Ke, Biomacromolecules 2017, 18, 4249. [11] a) J. Bieschke, M. Herbst, T. Wiglenda, R. P. Friedrich, A. Boeddrich, F. Schiele, D. Kleckers, J. M. Lopez del Amo, B. A. Grüning, Q. Wang, M. R. Schmidt, R. Lurz, R. Anwyl, S. Schnoegl, M. Fändrich, R. F. Frank, B. Reif, S. Günther, D. M. Walsh, E. E. Wanker, Nat. Chem. Biol. 2012, 8, 93; b) A. Kakinen, J. Adamcik, B. Wang, X. Ge, R. Mezzenga, T. P. Davis, F. Ding, P. C. Ke, Nano Res. 2018, 11, 3636. [12] a) S. Bolisetty, R. Mezzenga, Nat. Nanotechnol. 2016, 11, 365; b) Y. Shen, L. Posavec, S. Bolisetty, F. M. Hilty, G. Nyström, J. Kohlbrecher, M. Hilbe, A. Rossi, J. Baumgartner, M. B. Zimmermann, R. Mezzenga, Nat. Nanotechnol. 2017, 12, 642.\n[13] Z. S. Al-Garawi, B. A. McIntosh, D. Neill-Hall, A. A. Hatimy, S. M. Sweet, M. C. Bagley, L. C. Serpell, Nanoscale 2017, 9, 10773. [14] a) J. M. Dowding, W. Song, K. Bossy, A. Karakoti, A. Kumar, A. Kim, B. Bossy, S. Seal, M. H. Ellisman, G. Perkins, W. T. Self, E. Bossy-Wetzel, Cell Death Differ. 2014, 21, 1622; b) D. K. Ban, S. Paul, ACS Appl. Mater. Interfaces 2016, 8, 31587; c) C. Li, R. Mezzenga, Nanoscale 2013, 5, 6207; d) M. Mahmoudi, O. Akhavan, M. Ghavami, F. Rezaeeef, S. M. A. Ghiasi, Nanoscale 2012, 4, 7322; e) Y. Liu, L.-P. Xu, W. Dai, H. Dong, Y. Wen, X. Zhang, Nanoscale 2015, 7, 19060; f) M. Li, A. Zhao, K. Dong, W. Li, J. Ren, X. Qu, Nano Res. 2015, 8, 3216; g) J. Wang, L. Liu, D. Ge, H. Zhang, Y. Feng, Y. Zhang, M. Chen, M. Dong, Chem. - Eur. J. 2018, 24, 3397. [15] X.-P. He, Q. Deng, L. Cai, C.-Z. Wang, Y. Zang, J. Li, G.-R. Chen, H. Tian, ACS Appl. Mater. Interfaces 2014, 6, 5379. [16] T. John, A. Gladytz, C. Kubeil, L. L. Martin, H. J. Risselada, B. Abel, Nanoscale 2018, 10, 20894. [17] A. Gladytz, B. Abel, H. J. Risselada, Angew. Chem., Int. Ed. 2016, 55, 11242. [18] M. Wang, A. Kakinen, E. H. Pilkington, T. P. Davis, P. C. Ke, Biomater. Sci. 2017, 5, 485. [19] M. Faria, M. Björnmalm, K. J. Thurecht, S. J. Kent, R. G. Parton, M. Kavallaris, A. P. R. Johnston, J. J. Gooding, S. R. Corrie, B. J. Boyd, P. Thordarson, A. K. Whittaker, M. M. Stevens, C. A. Prestidge, C. J. H. Porter, W. J. Parak, T. P. Davis, E. J. Crampin, F. Caruso, Nat. Nanotechnol. 2018, 13, 777. [20] L. Breydo, B. Newland, H. Zhang, A. Rosser, C. Werner, V. N. Uversky, W. Wang, Biochem. Biophys. Res. Commun. 2016, 469, 830. [21] R. Limbocker, S. Chia, F. S. Ruggeri, M. Perni, R. Cascella, G. T. Heller, G. Meisl, B. Mannini, J. Habchi, T. C. T. Michaels, P. K. Challa, M. Ahn, S. T. Casford, N. Fernando, C. K. Xu, N. D. Kloss, S. I. A. Cohen, J. R. Kumita, C. Cecchi, M. Zasloff, S. Linse, T. P. J. Knowles, F. Chiti, M. Vendruscolo, C. M. Dobson. Nat. Commun. 2019, 10, 225. [22] D. M. Fowler, A. V. Koulov, C. Alory-Jost, M. S. Marks, W. E. Balch, J. W. Kelly, PLoS Biol. 2006, 4, 0100. [23] a) N. Gao, H. Sun, K. Dong, J. Ren, T. Duan, C. Xu, X. Qu, Nat. Commun. 2014, 5, 3422; b) Q. Luo, Y.-X. Lin, P.-P. Yang, Y. Wang, G.-B. Qi, Z.-Y. Qiao, B.-N. Li, K. Zhang, J.-P. Zhang, L. Wang, H. Wang, Nat. Commun. 2018, 9, 1802; c) Y. Zhao, J. Cai, Z. Liu, Y. Li, C. Zheng, Y. Zheng, Q. Chen, H. Chen, F. Ma, Y. An, L. Xiao, C. Jiang, L. Shi, C. Kang, Y. Liu, Nano Lett. 2019, 19, 674; d) Q. Chen, Y. Du, K. Zhang, Z. Liang, J. Li, H. Yu, R. Ren, J. Feng, Z. Jin, F. Li, J. Sun, M. Zhou, Q. He, X. Sun, H. Zhang, M. Tian, D. Ling, ACS Nano 2018, 12, 1321. [24] a) D. Kim, J. M. Yoo, H. Hwang, J. Lee, S. H. Lee, S. P. Yun, M. J. Park, M. Lee, S. Choi, S. H. Kwon, Nat. Nanotechnol. 2018, 13, 812; b) J. F. Poduslo, K. L. Hultman, G. L. Curran, G. M. Preboske, R. Chamberlain, M. Marjańska, M. Garwood, C. R. Jack Jr., T. M. Wengenack, J. Neuropathol. Exp. Neurol. 2011, 70, 653. [25] J.-C. Dodart, K. R. Bales, S. M. Paul, Trends Mol. Med. 2003, 9, 85. [26] Y. Z. Wadghiri, E. M. Sigurdsson, M. Sadowski, J. I. Elliott, Y. Li,\nH. Scholtzova, C. Y. Tang, G. Aguinaldo, M. Pappolla, K. Duff, Magn. Reson. Med. 2003, 50, 293. [27] Q. Song, M. Huang, L. Yao, X. Wang, X. Gu, J. Chen, J. Chen, J. Huang, Q. Hu, T. Kang, ACS Nano 2014, 8, 2345. [28] I. Javed, T. Yu, G. Peng, M. Zhao, A. Faridi, R. Mezzenga, T. P. Davis, S. Lin, P. C. Ke, Nano Lett. 2018, 18, 5797. [29] a) A. Faridi, Y. Sun, Y. Okazaki, G. Peng, J. Gao, A. Kakinen, P. Faridi, M. Zhao, I. Javed, A. W. Purcell, T. P. Davis, S. Lin, R. Oda, F. Ding, P. C. Ke, Small 2018, 14, 1802825; b) M. Li, S. E. Howson, K. Dong, N. Gao, J. Ren, P. Scott, X. Qu, J. Am. Chem. Soc. 2014, 136, 11655; c) Y. Guan, Z. Du, N. Gao, Y. Cao, X. Wang, P. Scott, H. Song, J. Ren, X. Qu, Sci. Adv. 2018, 4, eaao6718.\nAdv. Mater. 2019, 1901690\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901690 (7 of 7)\n[30] D. Carradori, A. Gaudin, D. Brambilla, K. Andrieux, Int. Rev. Neurobiol. 2016, 130, 73. [31] a) N. Cremades, S. I. A. Cohen, E. Deas, A. Y. Abramov, A. Y. Chen, A. Orte, M. Sandal, R. W. Clarke, P. Dunne, F. A. Aprile, C. W. Bertoncini, N. W. Wood, T. P. J. Knowles, C. M. Dobson, D. Klenerman, Cell 2012, 149, 1048; b) G. Fusco, S. W. Chen,\nP. T. F. Williamson, R. Cascella, M. Perni, J. A. Jarvis, C. Cecchi, M. Vendruscolo, F. Chiti, N. Cremades, L. Ying, C. M. Dobson, A. De Simone, Science 2017, 358, 1440; c) Y. Sun, A. Kakinen, Y. Xing, P. Faridi, A. Nandakumar, A. W. Purcell, T. P. Davis, P. C. Ke, F. Ding, Small 2019, 15, 1805166.\n[32] M. Ma, N. Gao, Y. Sun, J. Ren, X. Qu, Small 2017, 13, 1701817.\nAdv. Mater. 2019, 1901690"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Prof. P. C. Ke, E. H. Pilkington, I. Javed, Dr. A. Kakinen, Prof. T. P. Davis ARC Center of Excellence in Convergent Bio-Nano Science and Technology Monash Institute of Pharmaceutical Sciences Monash University 381 Royal Parade, Parkville, VIC 3052, Australia E-mail: pu-chun.ke@monash.edu; thomas.p.davis@monash.edu Prof. Y. Sun, Prof. F. Ding Department of Physics and Astronomy Clemson University Clemson, SC 29634, USA",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}